Markets:

Overview

News

Currencies

International

Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

716.38 -3.50 (-0.49%)

Streaming Delayed Price Updated: 3:03 PM EDT, May 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

62 63 Next >

Beyond The Numbers: 15 Analysts Discuss Regeneron Pharmaceuticals Stock ↗

August 04, 2025

Via Benzinga

Is Regeneron Pharmaceuticals Gaining or Losing Market Support? ↗

August 04, 2025

Via Benzinga

2 Biotech Stocks That Could Soar 29% and 165% According to Wall Street's Top Analysts ↗

August 03, 2025

These biotech businesses look compelling for very different reasons.

Via The Motley Fool

Regeneron (REGN) Q2 EPS Jumps 53% ↗

August 02, 2025

Via The Motley Fool

Why Regeneron (REGN) Stock Is Trading Up Today

August 01, 2025

Shares of biotech company Regeneron (NASDAQ:REGN) jumped 3.3% in the morning session after the company reported strong second-quarter financial results that significantly surpassed analyst...

Via StockStory

Topics Artificial Intelligence

Stocks Sell Off, Gold Rallies On Tariff Turmoil, Weak Jobs Data: What's Moving Markets Friday? ↗

August 01, 2025

It's a rough start to the new month for Wall Street, as major U.S. stock indices plunged by midday Friday, setting the stage for a negative weekly close.

Via Benzinga

4D Molecular Therapeutics Rallies On Heels Of Diabetes-Related Vision Study ↗

August 01, 2025

4D Molecular's 4D-150 showed sustained vision and anatomical improvements with fewer injections in DME, supported by regulatory alignment.

Via Benzinga

Regeneron's Pipeline Hit By Catalent Delays, But Dupixent Shines ↗

August 01, 2025

Regeneron Q2 revenue rose 4% to $3.68 billion, driven by Dupixent and antibody profits, while FDA delays impacted Eylea HD and odronextamab approvals.

Via Benzinga

Regeneron Pharmaceuticals (NASDAQ:REGN) Beats Q2 2025 Earnings Estimates but Faces Muted Market Reaction ↗

August 01, 2025

Regeneron Q2 2025 earnings beat estimates with $3.68B revenue and $12.89 EPS, but stock dips in pre-market trading. Dupixent sales surge 22% to $4.34B.

Via Chartmill

Topics Earnings

Regeneron’s (NASDAQ:REGN) Q2: Strong Sales

August 01, 2025

Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 3.6% year on year to $3.68 billion. Its non-GAAP profit of $12.89 per share was...

Via StockStory

Regeneron Reports Second Quarter 2025 Financial and Operating Results

August 01, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Regeneron Pharmaceuticals Likely To Report Lower Q2 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call ↗

August 01, 2025

Via Benzinga

Earnings Scheduled For August 1, 2025 ↗

August 01, 2025

Via Benzinga

Trump Turns Up Heat On Big Pharma CEOs To Slash Drug Prices Within 60 Days — But Retail Traders Don't Flinch ↗

July 31, 2025

Via Stocktwits

Topics Government

Exploring Regeneron Pharmaceuticals's Earnings Expectations ↗

July 31, 2025

Via Benzinga

Regeneron (REGN) Q2 Earnings: What To Expect

July 30, 2025

Biotech company Regeneron (NASDAQ:REGN) will be reporting earnings this Friday before market open. Here’s what investors should know.

Via StockStory

Topics Artificial Intelligence Government World Trade

2 Healthcare Stocks That Are Losing to the S&P 500 This Year ↗

July 27, 2025

Wall Street might be underestimating these companies' potential.

Via The Motley Fool

Topics Stocks

$1000 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth This Much Today ↗

July 25, 2025

Via Benzinga

Regeneron Announces the 2025 Winners of the Regeneron Prize for Creative Innovation

July 24, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

3 Low-Volatility Stocks We Steer Clear Of

July 24, 2025

A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.

Via StockStory

Trump Tariffs Forces AstraZeneca To Bring Substantial Pharmaceutical Production To US ↗

July 22, 2025

AstraZeneca plans a $50 billion investment in U.S. facilities by 2030, including a Virginia plant focused on weight loss and metabolic drugs.

Via Benzinga

Topics Government

After Falling 68%, Where Will This Weight-Loss Drug Stock Be in 2 Years? History Shows Massive Gains Ahead. ↗

July 19, 2025

Yet another biopharma name has been run through a familiar trading cycle that often ends on a bullish note.

Via The Motley Fool

Topics Intellectual Property

How Is The Market Feeling About Regeneron Pharmaceuticals? ↗

July 17, 2025

Via Benzinga

1 Healthcare Stock on Our Buy List and 2 to Brush Off

July 15, 2025

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the...

Via StockStory

Topics Stocks

Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies ↗

July 11, 2025

Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest.

Via Benzinga

Topics Government World Trade

Assessing Regeneron Pharmaceuticals: Insights From 26 Financial Analysts ↗

July 10, 2025

Via Benzinga

1 Cash-Heavy Stock to Own for Decades and 2 to Ignore

July 08, 2025

Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits,...

Via StockStory

23andMe’s $305M Sale To Co-Founder Wojcicki Approved: California Loses Legal Battle Over DNA Privacy ↗

July 07, 2025

A U.S. bankruptcy judge ruled that California's appeal to block the deal was unlikely to succeed, rejecting claims that the sale violated state genetic privacy laws.

Via Stocktwits

Topics Bankruptcy

Apogee Reverses Lower Despite Promise For Twice-Yearly Eczema Shot ↗

July 07, 2025

Apogee Therapeutics shares crumbled Monday despite promising results for what could become a twice-yearly eczema shot.

Via Investor's Business Daily

Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs

July 07, 2025

Via Investor Brand Network

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

62 63 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.